TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis: Erratum

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2021; 11(5):2079. doi:10.7150/thno.56734

Erratum

Han-Li Huang1,2, Yi-Min Liu1, Ting-Yi Sung2, Tsui-Chin Huang3, Ya-Wen Cheng3, Jing-Ping Liou1,4, Corresponding address, Shiow-Lin Pan1,2,3, Corresponding address

1. TMU Biomedical Commercialization Center, Taipei Medical University, Taipei 11031, Taiwan
2. Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
3. Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
4. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Citation:
Huang HL, Liu YM, Sung TY, Huang TC, Cheng YW, Liou JP, Pan SL. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis: Erratum. Theranostics 2021; 11(5):2079. doi:10.7150/thno.56734. Available from https://www.thno.org/v11p2079.htm

Corrected-article in Theranostics, Volume 9, 6676

The authors wish to inform readers of a correction to the study. The informed consent and the IRB approval number in the Materials and methods section, should be revised as follows:

The human tissue biopsy samples used in this study were collected as part of a study approved by the human ethics committee of Taipei Medical University Joint Institutional Review Board (TMU-JIRB No. N201701061). The waiver of informed consent for the study was monitored by TMU-JIRB.

The authors regret the inconsistency and apologize for not identifying the issue earlier in the publication process.

Corresponding address Corresponding authors: Shiow-Lin Pan, Ph.D. Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, No. 250 Wuxing Street, Taipei 11031, Taiwan. E-mail: slpanedu.tw. Phone: 886-2-27361661 ext 7671. Jing-Ping Liou, Ph.D. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. No. 250, Wuxing St., Taipei 11031, Taiwan. E-mail address: jpledu.tw. Phone: 886-2-27361661 ext 6130

Published 2021-1-1

留言 (0)

沒有登入
gif